Anrotinib hydrochloride is a multi-targeted complex kinase inhibitor that inhibits tumor angiogenesis and inhibits tumor growth. It can be used to treat many malignancies in humans, such as non-small cell lung cancer, small cell lung cancer, soft tissue sarcoma, and advanced kidney cancer. If this targeted drug is effective, patients usually do not need to stop taking it and can continue to take it. Once the drug is stopped, there is a possibility that the tumor will recur and progress, and sometimes drug resistance will occur if the drug is taken again, so it is necessary to consider stopping the drug and replacing it with other therapeutic drugs. Some patients may have serious adverse reactions such as rash and diarrhea after taking Anrotinib Hydrochloride, so they can consider reducing the dosage first, and if they can’t stand it, they need to stop the drug.